• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    MPO's 2023 Medtech Supply Chain Survey

    Exceeding Medical Device Extrusion Expectations

    Medical Device Micromolders Discuss the 'Minor Details'

    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—Sept. 30

    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman

    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device

    ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany

    Siemens Healthineers’ Magnetom Viato.Mobile Cleared by FDA
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    MPO's 2023 Medtech Supply Chain Survey

    Exceeding Medical Device Extrusion Expectations

    Medical Device Micromolders Discuss the 'Minor Details'

    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Back to School for Medical Device Cybersecurity Training

    Driving Clinical Trial Excellence to Help Study Teams Run a Faster Relay Race

    Medtech’s Supply Chain: From Disruption to Opportunity

    Are Medtech’s Mega-Deals Gone For Good?

    Will a Skilling Gap Hinder Organizational Readiness for Medtech’s New Age of AI?
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Providence Enterprise USA Inc.

    Cirtec Medical

    LEMO USA Inc.

    Medbio LLC

    Johari Digital Healthcare Ltd.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How Wearables Are Changing the Way We Collect Real-World Data in Clinical Trials

    Could Medtech Ever Stop a Hospital Killer in Their Tracks?

    A One-Stop-Shop, Turnkey Solution Is Paramount for Success

    How Additive and Subtractive Manufacturing Are Revolutionizing the Medical Device Industry

    Medical Device Commercialization: It’s What, Not When, to Transfer to Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Providence Enterprise USA Inc.

    Cirtec Medical

    LEMO USA Inc.

    Medbio LLC

    Johari Digital Healthcare Ltd.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Features

    India’s New Medical Devices Rules

    The country’s MDR has eight provisions every manufacturer should know if interested in doing business in India.

    India’s New Medical Devices Rules
    Companies that become acquainted with the new regulatory rules set in place by India’s Ministry of Health and Family Welfare stand to be at an advantage to serve the country’s 1 billion plus potential patient population.
    Blake E. Wilson and Shilpa Prem, Hogan Lovells04.03.18
    In January 2017, India’s Ministry of Health and Family Welfare released the long-awaited Medical Device Rules of 2017 (MDR 2017 or the Act), which took effect on Jan. 1, 2018. Upon implementation, this regulation replaced the existing Drugs and Cosmetics Act (DCA).

    Prior to implementation of the Act, the medical device industry in India was largely unregulated, except for a few devices1 covered specifically by the DCA. The list of covered devices was limited (only 15 medical devices were included), and the DCA treated these devices as drugs rather than establishing regulations tailored to the medical device industry. The implementation of MDR 2017 attempts to establish a uniform regime for Indian medical device manufacturing and marketing. The structure of this regulatory paradigm appears to be on par with global norms, including the EU’s Medical Device Regulation, although the extent of these similarities will depend upon India’s implementation of the Act.

    It is expected that the global medical devices and technology market will grow to USD 529.8 billion by 2022 from an estimated USD 371 billion in 2015.2 The Indian market is among the top 20 in the world by market size, and fourth in Asia after Japan, China, and South Korea.3

    Currently, 75 percent of medical device sales in India are derived from imports.3 A range of factors contribute to the high percentage of imports, including the absence of a concrete regulatory framework specific to medical devices, which has been believed to have constrained investments in the market.

    Business growth has been of utmost importance for the Indian government. During the Wharton India Economic Forum, held Nov. 12, 2017, business leaders around the world echoed the theme of the “Make in India” campaign—a government program rolled out in 2016 to provide a more favorable environment for domestic manufacturers in the hopes of encouraging more long-term investments. As part of the “Make in India” campaign, implementing medical device regulations was a strategic effort to enhance the business environment, thereby encouraging the domestic development and manufacturing of medical devices.

    Central Government and State Government bodies will be responsible for implementation and enforcement of MDR 2017. Medical device approvals will be conducted by the Drugs Controller General of India (DCGI) who will also be responsible for overseeing clinical trials, import licenses, and device classifications.

    Following are eight notable provisions from India’s new medical device regulations that will impact both domestic and foreign medical device developers and manufacturers wanting to do business in India.

    1. Medical devices and in-vitro diagnostics will be classified into four categories, depending upon the indications for use and risk level of the device.
    The new rules establish a risk-based approach, whereby the level of regulation varies considerably depending on the risks and technology associated with the device’s intended use and technological characteristics. Four classes (Class A, B, C, and D) have been established under the new framework, where Class A and B present the least risk and Class C and D devices present higher risk to patients.4 For example, an elastic bandage or a mechanical barrier used for compression or for absorption of exudates for wounds that have not breached the dermis and can heal by primary intention would be classified as a Class A device.5 An example of a Class B medical device is contact lenses6 whereas a blood bag that does not incorporate a medicinal product would be considered a Class C device.7 Finally, a transient-use surgically invasive medical device intended to be used specifically in direct contact with the central nervous system or for the diagnosis, monitoring, or correction of a heart defect or central circulatory system condition through direct contact with body parts would be an example of a Class D device.8

    2. DCGI determines device classification.
    As compared to the U.S. Food and Drug Administration (FDA), the DCGI classifies all proposed medical devices.9 In the United States, manufacturers and importers classify their products for the purposes of registration and propose device classifications in marketing applications (although FDA has the ability to reject proposed classifications). Conversely, in India, the license authority will classify the medical device based on the intended use of the device and other factors, such as the invasiveness of the device, duration of device use, presence of an “active therapeutic/diagnostic,” and whether the medical device incorporates medicinal product/human cells/tissues/derivatives.10

    It should be noted that accessories will be classified separately from the parent device.10 If the device is intended to be used in combination with another device, the classification rules will apply separately to each of the devices.

    3. Inspections are required for all new Class C and D medical devices.
    Similar to the requirements of the EU Medical Device Rules, before the government grants an entity a license to manufacture or distribute a device that is classified as either a Class C or D product, the manufacturing site will be inspected within a period of 60 days from the date of the marketing application by notified bodies or other delegated government entities to verify conformance with quality management system regulations.11 Further, an inspection report will be completed by the inspection team with recommendations and findings that will be provided to the licensing authority. Once the inspection report has been received, the government will have 45 days to either grant a license to manufacture/distribute the device or reject the application.11

    4. All proposed medical devices will be expected to conform to performance standards.
    Medical devices will need to conform to performance standards imposed by the Bureau of Indian Standards (BIS) or as prescribed by the Ministry of Health and Family Welfare in the Central Government. The rule further states that if there are no relevant standards recommended by BIS, then relevant standards released by the International Organization for Standardization (ISO) or the International Electro Technical Commission (IEC), or by any other pharmacopoeial standard would need to be followed. If no relevant standards exist, then the validated manufacturer’s standards will need to be used.12

    5. Timelines have been specified.
    The rules specify timelines for various actions. For example, the review of a marketing application for a Class C or Class D medical device must be completed within 45 days from the date of the online submission.13 Further, inspection of the manufacturing site for medical devices classified as Class C or Class D must be completed within 60 days from the date of the initial application.14 Furthermore, after completion of the inspection, the inspection team must forward the inspection report to the licensing authority, who then has 45 days to make a final approval determination.15 Setting forth timelines in the Act provides hope that the application process will be transparent. As these rules only took effect in January 2018, it remains to be seen whether the Central Government and State Government bodies, in conjunction with the DCGI, will adhere to these set timelines.

    6. Licenses are perpetual.
    Medical device licenses that are granted will remain valid in perpetuity, as long as license fees are paid every five years from the date of issue, unless the license is suspended or cancelled by the licensing authority.16 If the licensee fails to pay the required license retention fee on or before the due date, the entity will be liable to pay late fees in addition to the license retention fee. If the licensee fails to deposit the license retention fee within 180 days, the license is deemed to have been cancelled. Therefore, continuous monitoring of granted licenses is required.16

    7. Prior approval is required for major medical device changes.
    Major changes require prior approval from the appropriate licensing authority.17 Examples of major changes include a change in material of construction, a design change that affects the quality, a change in the intended use or indications for use, a change in performance and stability, change in method of sterilization or approved shelf life, change of domestic manufacturer name, or change of manufacturing site. The licensing authority must approve or reject the change within 45 days.17
    Minor changes (e.g., changes that will not affect quality) only require written notice to the appropriate licensing authority within a period of 30 days of making the change.18

    8. Clinical investigation framework added.
    The Medical Device Rules have added a new regulatory framework for clinical investigations.19 The government requires that clinical investigations in humans be approved prior to initiation. Further, permission must be obtained to import or manufacture investigational medical devices to conduct clinical investigations.20

    Further Reference
    Other notable provisions include the following:

    • The licensing agency has 90 days from the time it receives an application to conduct a clinical investigation to either approve or grant permission to conduct the study.21
    • No approval is required for academic clinical studies on licensed medical devices where the Ethics Committee approves such a study and the data generated during the study is not used for a marketing application.

    The rule has conditions that must be met once a clinical study protocol has been approved.22

    • The clinical investigation must be initiated within a period of one year from the date of approval.
    • The clinical investigation must be registered with the Clinical Trial Registry of India before enrolling the first participant.
    • Annual status reports must be submitted to the licensing authority, including notification of termination of the study, and the reporting of suspected or unexpected serious adverse events occurring during the clinical investigation within 14 days of knowledge of its occurrence.

    Conclusion
    Implementing a detailed regulatory framework may lead to enhanced data generation and overall greater confidence in the safety and effectiveness of devices developed and manufactured in India.

    The Indian Government has emphasized the importance of the medical device industry through its “Make in India” initiative.23 A task force was specifically developed to implement a range of recommendations to promote medical device manufacturing in India, which included the separation of medical devices from the drug laws.

    Further, it is believed that these rules will enhance the ease of conducting business in India by setting transparent requirements, expectations, and timelines to ensure that safe and effective medical devices are able to enter the market on a global scale.

    References
    1. Devices regulated by the Drugs and Cosmetic Act of 1945 were known as “Notified Medical Devices.”
    2. EvaluateMedTech World Preview 2017, Outlook to 2022. http://bit.ly/mpo180454
    3. Deloitte and NATHEALTH, Medical Devices—Making in India—A leap for Indian Healthcare, 2016. http://bit.ly/mpo180450 [PDF]
    4. Ministry of Health and Family Welfare [http://bit.ly/mpo180453 (PDF)]—Part II, Sec. 3(i); Chapter II, #4 (page 146).
    5. Ibid—Part I, Sec. 1(i)(a); First Schedule (page 167).
    6. Ibid—Part I, Sec. 1(v)(b); First Schedule (page 168).
    7. Ibid—Part I, Sec. 1(ii)(c); First Schedule (page 167).
    8. Ibid—Part I, Sec. 1(ix)(g); First Schedule (page 168).
    9. Ibid—Part II, Sec. 3(i); Chapter IV, #4 (page 146).
    10. Ibid—Part II, Sec. 3(i); First Schedule (page 167).
    11. Ibid—Part II, Sec. 3(i); Chapter IV, #23-25 (page 150).
    12. Ibid—Part II, Sec. 3(i); Chapter IV, #7 (page 146).
    13. Ibid—Part II, Sec. 3(i); Chapter IV, #21 (page 149).
    14. Ibid—Part II, Sec. 3(i); Chapter IV, #2 (page 150).
    15. Ibid—Part II, Sec. 3(i); Chapter IV, #24-25 (page 150).
    16. Ibid—Part II, Sec. 3(i); Chapter IV, #29 (page 151).
    17. Ibid—Part II, Sec. 3(i); Chapter IV, #26 (page 150).
    18. Ibid—Part II, Sec. 3(i); Chapter IV, #26 (page 151).
    19. Ibid—Part II, Sec. 3(i); Chapter VII (page 157).
    20. Ibid—Part II, Sec. 3(i); Seventh Schedule (page 202).
    21. Ibid—Part II, Sec. 3(i); Chapter IV, #52 (page 157).
    22. Ibid—Part II, Sec. 3(i); Chapter IV, #53 (page 158).
    23. http://bit.ly/mpo180452


    Blake Wilson is a senior associate in the Regulatory practice at Hogan Lovells in Philadelphia, Pa. He advises clients on matters related to the U.S. Food and Drug Administration’s regulation of medical devices, with a particular focus on premarket approval or clearance.

    Shilpa Prem is an associate in the Regulatory practice at Hogan Lovells in Philadelphia. She represents clients in FDA medical device approval and clearance associated matters and conducts regulatory due diligence for medical device manufacturers in mergers, acquisitions, joint ventures, and private equity/venture capital investments deals.
    Related Searches
    • japan
    • regulatory
    • regulations
    • change
    Suggested For You
    MEDICAL & BIOTECH MANUFACTURING MEDICAL & BIOTECH MANUFACTURING
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board

    Related Literature / Brochures

    • MEDICAL & BIOTECH MANUFACTURING

      ISO 13485:2016 • FDA Registered

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21


    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    Loading, Please Wait..

    Trending
    • ZOLL Expands Temperature Management Portfolio To Include IQool System
    • Diabetes Innovation: MIT Engineers Unveil Implantable Device With Oxygen Factory
    • Siemens Healthineers Presents Mammomat B.brilliant
    • Danaher Names New Environmental And Applied Solutions Company Veralto
    • A New Approach To Post-Market Surveillance
    Breaking News
    • MPO's Most-Read Stories This Week—Sept. 30
    • Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    • SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    • ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
    • Siemens Healthineers’ Magnetom Viato.Mobile Cleared by FDA
    View Breaking News >
    CURRENT ISSUE

    October 2023

    • MPO's 2023 Medtech Supply Chain Survey
    • Exceeding Medical Device Extrusion Expectations
    • Medical Device Micromolders Discuss the 'Minor Details'
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login